JP2011518178A - 病的血管形成および脈管透過性の処置用の組成物および方法 - Google Patents

病的血管形成および脈管透過性の処置用の組成物および方法 Download PDF

Info

Publication number
JP2011518178A
JP2011518178A JP2011505210A JP2011505210A JP2011518178A JP 2011518178 A JP2011518178 A JP 2011518178A JP 2011505210 A JP2011505210 A JP 2011505210A JP 2011505210 A JP2011505210 A JP 2011505210A JP 2011518178 A JP2011518178 A JP 2011518178A
Authority
JP
Japan
Prior art keywords
robo4
composition
angiogenesis
activation
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011505210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518178A5 (OSRAM
Inventor
リ ディーン
ジョーンズ クリストファー
ロンドン ネイル
Original Assignee
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティー オブ ユタ リサーチ ファウンデーション filed Critical ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Publication of JP2011518178A publication Critical patent/JP2011518178A/ja
Publication of JP2011518178A5 publication Critical patent/JP2011518178A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
JP2011505210A 2008-04-16 2009-04-16 病的血管形成および脈管透過性の処置用の組成物および方法 Pending JP2011518178A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4558008P 2008-04-16 2008-04-16
US61/045,580 2008-04-16
US7388008P 2008-06-19 2008-06-19
US61/073,880 2008-06-19
PCT/US2009/040848 WO2009129408A2 (en) 2008-04-16 2009-04-16 Compositions and methods for treating pathologic angiogenesis and vascular permeability

Publications (2)

Publication Number Publication Date
JP2011518178A true JP2011518178A (ja) 2011-06-23
JP2011518178A5 JP2011518178A5 (OSRAM) 2012-07-26

Family

ID=41199735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011505210A Pending JP2011518178A (ja) 2008-04-16 2009-04-16 病的血管形成および脈管透過性の処置用の組成物および方法

Country Status (8)

Country Link
US (1) US20100222401A1 (OSRAM)
EP (1) EP2262524A4 (OSRAM)
JP (1) JP2011518178A (OSRAM)
KR (1) KR20100133881A (OSRAM)
CN (1) CN101687014A (OSRAM)
BR (1) BRPI0903901A2 (OSRAM)
CA (1) CA2693001A1 (OSRAM)
WO (1) WO2009129408A2 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017516860A (ja) * 2014-05-27 2017-06-22 ナビゲン，インコーポレーテッド Ａｒｆ６阻害剤並びにそれらの合成方法及び使用
JP2018508528A (ja) * 2015-03-02 2018-03-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 血管新生阻害ペプチド

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512327A (ja) 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 病的血管形成および脈管透過性の処置用の組成物および方法
US8620879B2 (en) * 2009-10-13 2013-12-31 Google Inc. Cloud based file storage service
US20110087603A1 (en) * 2009-10-13 2011-04-14 Google Inc. Cloud based media player and offline media access
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用
US8399404B2 (en) 2010-06-15 2013-03-19 The Hospital For Sick Children Methods and uses for inhibiting platelet coagulation
US10561707B2 (en) * 2013-09-08 2020-02-18 Technion Research And Development Foundation Ltd. Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
CN105726534A (zh) * 2016-02-17 2016-07-06 上海交通大学医学院附属仁济医院 SecinH3在制备抑制胃酸分泌药物中的应用
WO2017173327A1 (en) * 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
CN108929383B (zh) * 2017-05-26 2021-10-15 阿思科力(苏州)生物科技有限公司 重组Slit2D2(C386S)-HSA融合蛋白及其在预防和/或治疗肺部炎症中的应用
US11077422B2 (en) * 2017-06-16 2021-08-03 Aquablok, Ltd. Spalling composite particles and methods of using them
CN108364289B (zh) * 2018-03-02 2021-05-14 成都斯斐德科技有限公司 Ivoct图像易损斑块自动检测方法
CN108715862A (zh) * 2018-05-28 2018-10-30 上海海洋大学 ddx19基因缺失斑马鱼突变体的制备方法
WO2021077064A1 (en) * 2019-10-18 2021-04-22 EMULATE, Inc. Brain-chip modeling neurodegeneration and neuroinflammation in parkinson's disease
WO2021184059A1 (en) * 2020-03-14 2021-09-23 Newsouth Innovations Pty Limited Treatment methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480975A (en) * 1994-02-08 1996-01-02 Brigham And Women's Hospital Induction of vascular endothelial growth factor (VEGF) by transition metals
US6372958B1 (en) * 1999-05-26 2002-04-16 The University Of Utah Research Foundation Transgenic mouse with endogenous endoglin gene disruption
US6960651B2 (en) * 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
AU2001283062A1 (en) * 2000-08-02 2002-02-13 The Johns Hopkins University Endothelial cell expression patterns
US7939497B2 (en) * 2002-03-08 2011-05-10 Shanghai Institutes For Biological Sciences, Cas Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
EP1534318A4 (en) * 2002-06-27 2009-07-01 Univ Utah Res Found METHOD AND COMPOSITIONS FOR MANIPULATING GUIDED NAVIGATION OF ENDOTHONE TUBES IN THE ANGIOGENESIS
DE102004055998A1 (de) * 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
DE102006054205A1 (de) * 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
JP2010512327A (ja) * 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 病的血管形成および脈管透過性の処置用の組成物および方法
CN102083452A (zh) * 2008-12-12 2011-06-01 犹他大学研究基金会 用于促进血管屏障功能和治疗肺纤维化的组合物和方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013059253; ＪＯＮＥＳ，　Ｃ．　Ａ．　ＥＴ　ＡＬ．: 'Ｒｏｂｏ４　ｓｔａｂｉｌｉｚｅｓ　ｔｈｅ　ｖａｓｃｕｌａｒ　ｎｅｔｗｏｒｋ　ｂｙ　ｉｎｈｉｂｉｔｉｎｇ　ｐａｔｈｏｌｏｇｉｃ　ａｎｇｉｏｇｅｎｅｓｉｓ　ａｎｄ　ｅｎｄｏｔｈｅｌｉａｌ　ｈｙｐｅｒｐｅｒ' ＮＡＴ．　ＭＥＤ． , 200803, ｐａｇｅｓ　４４８　-　４５３, ｖｏｌ．　１４，　ｎｏ．　４ *
JPN6013059256; ＰＡＲＫ，　Ｋ．　Ｗ．　ＥＴ　ＡＬ．: 'Ｒｏｂｏ４　ｉｓ　ａ　ｖａｓｃｕｌａｒ-ｓｐｅｃｉｆｉｃ　ｒｅｃｅｐｔｏｒ　ｔｈａｔ　ｉｎｈｉｂｉｔｓ　ｅｎｄｏｔｈｅｌｉａｌ　ｍｉｇｒａｔｉｏｎ' ＤＥＶ．　ＢＩＯＬ． , 2003, ｐａｇｅｓ　２５１　-　２６７, ｖｏｌ．　２６１ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017516860A (ja) * 2014-05-27 2017-06-22 ナビゲン，インコーポレーテッド Ａｒｆ６阻害剤並びにそれらの合成方法及び使用
US10849901B2 (en) 2014-05-27 2020-12-01 Navigen, Inc. Arf6 inhibitors and methods of synthesis and use thereof
JP2018508528A (ja) * 2015-03-02 2018-03-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 血管新生阻害ペプチド

Also Published As

Publication number Publication date
EP2262524A4 (en) 2012-07-11
KR20100133881A (ko) 2010-12-22
CN101687014A (zh) 2010-03-31
BRPI0903901A2 (pt) 2017-05-23
EP2262524A2 (en) 2010-12-22
WO2009129408A2 (en) 2009-10-22
WO2009129408A3 (en) 2009-12-23
US20100222401A1 (en) 2010-09-02
CA2693001A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
JP2011518178A (ja) 病的血管形成および脈管透過性の処置用の組成物および方法
US7994130B2 (en) Compositions and methods for treating ocular pathologic angiogenesis and vascular permeability
Lin et al. VEGF‐C/VEGFR‐3 axis protects against pressure‐overload induced cardiac dysfunction through regulation of lymphangiogenesis
Kim et al. IL-37 attenuates lung fibrosis by inducing autophagy and regulating TGF-β1 production in mice
Van Obberghen-Schilling et al. Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth
Marshall et al. Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy
JP2019536813A (ja) Ｓａｓｐモジュレータおよび老化アテニュエータを含む組成物、ならびに細胞老化を調節するためのその使用
KR20110102142A (ko) 혈관 장벽 기능을 촉진하고 폐 섬유증을 치료하기 위한 조성물 및 방법
US20050119198A1 (en) Novel target to inhibit angiogenesis
JP2024156834A (ja) Ｃｄ１４６と、それをバイオマーカーとして線維症の診断に使用すること及び治療ターゲットとして線維症の治療において使用すること
Grisaru‐Granovsky et al. PAR1&2 driven placenta EVT invasion act via LRP5/6 as coreceptors
Zhou et al. Postinfarction healing dynamics in the mechanically unloaded rat left ventricle
US20110086089A1 (en) Use of p27kip1 for the prevention and treatment of heart failure
US8080252B2 (en) Compounds and methods of modulating angiogenesis
Hung Regulation of Muscle Stem Cell Quiescence by Niche Adhesion
Mastej The Role of KLF4 and KLF2 Crosstalk in Endothelial to Mesenchymal Transition and Pulmonary Fibrosis
EP2068877A2 (en) Compounds and methods of modulating angiogenesis
Daskalopoulos et al. Effect of Interventions in WNT Signaling on Healing of Cardiac Injury: A Systematic Review. Cells 2021, 10, 207
Bracey Characterization of NLRP3 in the Maintenance of Cardiac Tissue Homeostasis
Beckett Novel Mechanism and Therapies for Fibrosis
Oas p120-catenin in vascular development and endothelial adhesion strengthening
Mariotti Molecular pathophysiology of cholangiopathies: lessons from polycystic and fibropolycystic liver disease
Stewart Characterising the in vitro and in vivo function of the RhoG effector DOCK4 during angiogenesis and ischemia.
Naugle Regulation of cardiac fibroblast function via cyclic AMP, collagen I, III, and VI: implications for post-infarction remodeling
HK1139589A (en) Compositions and methods for treating pathologic angiogenesis and vascular permeability

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140520